Ann: Imugene doses first patient in nextHERIZON Phase 2 trial, page-20

Imugene’s M.D. & CEO, Ms Leslie Chong said: “Evidence to date has shown the potential to overcome resistance to immunotherapy within GI cancers by increasing cytotoxic and effector immune cells within the tumour microenvironment. Immunotherapies such as HER-Vaxx, particularly in combination with immune checkpoint inhibitors such as pembrolizumab, may hold the solution. With the promising results we've seen from HER-Vaxx thus far, we're particularly eager to take the next step in its development with this trial and ideally improve outcomes for patients with this difficult to treat cancer.”

Reading the above paragraph of the announcement, imagine if this trial proves that combination with immune checkpoint inhibitors such as Keytruda works, then the implication will be huge for IMU's whole B cell platform. Don't forget there is that PD1vaxx combo with Tecentriq to come as well. If this combo trials proves up LC's theory that it works, chances are not only will Merck pounce, Roche would most likely pounce on PD1vaxx as well so as not to miss out.

Next year could well be huge for the whole B cell platform future.